Synthesis and biological evaluation of nitrogen-containing benzophenone analogues as TNF-α and IL-6 inhibitors with antioxidant activity

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 7, 2010, Pages 2292-2296

  Bandgar, Babasaheb P ^a,b   Patil, Sachin A ^b   Totre, Jalinder V ^b   Korbad, Balaji L ^b   Gacche, Rajesh N ^b   Hote, Baliram S ^b   Jalde, Shivkumar S ^b   Chavan, Hemant V ^a  

^a SOLAPUR UNIVERSITY   (India)

^b SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

Author keywords

Anti inflammatory; Antioxidant activity; IL 6; Nitrogen containing benzophenone; TNF

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; BENZOPHENONE DERIVATIVE; CHOLECYSTOKININ OCTAPEPTIDE; DEXAMETHASONE; INTERLEUKIN 6; NITROGEN; PIPERAZINE; SCAVENGER; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CYTOKINE RELEASE; CYTOTOXICITY; HUMAN; HUMAN CELL; KINETICS; MANNICH REACTION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TOXICITY;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BENZOPHENONES; CELL LINE; HUMANS; INTERLEUKIN-6; NITROGEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949490562     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.001     Document Type: Article

References (36)

1. Dinarello C.A. Curr. Opin. Immunol. 3 (1991) 941
2. Arend W.P., and Dayer J.M. Arthritis Rheum. 33 (1990) 305
3. Dayer J.M., and Demczuk S. Springer Semin. Immunopathol. 3 (1984) 387
4. Barnes P.J., Chung K.F., and Page C.P. Update Pharmacol Rev. 50 (1998) 515
5. Loyau G., and Punol J.P. Scand. J. Rheumatol. Suppl. 81 (1990) 8
6. Kirkham B. Ann. Rheum. Dis. 50 (1991) 395
7. Nickoloff B.J. Arch. Dermatol. 135 (1991) 1104
8. Saklavala J., Davis W., and Guesdon F. Philos. Trans. R. Soc. London, Ser. B. 351 (1996) 151
9. Sacca R., Cuff C.A., and Ruddle N.H. Curr. Opin. Immunol. 9 (1997) 851
10. Matsui T., Kondo T., Nishita Y., Itadani S., Nakatani S., Omawari N., Sakai M., Nakazawa S., Ogata A., Ohno H., Obata T., Nakaia H., and Toda M. Bioorg. Med. Chem. Lett. 12 (2002) 903
11. Palladino M.A., Bahjat F.R., Theodorakis E.A., and Moldawer L.L. Nat. Rev. Drug. Disc. 2 (2003) 736
12. Tracey D., Klareskog L., Sasso E., Salfeld J., and Tak P. Pharmacol. Ther. 117 (2008) 244
13. Dominic S.C.R. Semin. Arthritis Rheum. 38 (2009) 382
14. Palomer A., Perez J.J., Navea S., Llorens O., Pascual J., Garcia M.L., and Mauleon D.M. J. Med. Chem. 43 (2000) 2280
15. Palomer A., Pascual J., Cabre M., Borras L., Gonzalez G., Aparici M., Carabaza M., Cabre F., Garcia M.L., and Mauleon D. Bioorg. Med. Chem. Lett. 12 (2002) 533
16. Jiri, J.; Miroslav, P.; Josef, P.; Stanislav, W. Czech CS 1991, 271, 185; Chem. Abstr. 1992, 117, 170994d.
17. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., and Chan C.C. Inflamm. Res. 45 (1996) 68
18. Williams M., Kowaluk E.A., and Arneric S.P. J. Med. Chem. 42 (1999) 1481
19. Venu T.D., Khanum S.A., Firdouse A., Manuprasad B.K., Shashikanth S., Mohamed R., and Vishwanth B.S. Bioorg. Med. Chem. Lett. 18 (2008) 440
20. Ottosen E.R., Sorensen M.D., Bjorkling F., Skak-Nieleson T., Fjording M.S., Aaes H., and Binderup L. J. Med. Chem. 46 (2003) 5651
21. Khanum S.A., Girish V., Suparshwa S.S., and Khanum N.F. Bioorg. Med. Chem. Lett. 19 (2009) 1887
22. Khanum S.A., Shashikanth S., and Deepak A.V. Bioorg. Chem. 32 (2004) 211
23. Murari S.K., Sriharsha S.N., Shashikanth S., and Vishwanath B.S. Bioorg. Med. Chem. Lett. 14 (2004) 2423
24. Revesz L., Blum E., Franco E., Di Padova T., Bhul R.F., Gram H., Hiestand P., Manning U., and Rucklin G. Bioorg. Med. Chem. Lett. 14 (2004) 3601
25. Kamble R.R., Belgur S.S., Aladkatti R., and Khaz I.A. Chem. Pharm. Bull. 16 (2009) 57
26. Ahluwalia V.K. Intermediates for Organic Synthesis (2005), New Delhi, I.K. International p. 192
27. Wilds A.L., Nowak R.M., and McCaleb K.E. Org. Synth. 4 (1963) 281
28. 3): 12.83 (s, 1H), 7.531-7.395 (m, 4H), 6.13 (d, 1H), 5.84 (d, 1H), 3.89 (s, 3H), 3.77 (s, 3H), MS: 277 [M+1].
29. 3): 7.664 (d, 1H, J = 8 Hz), 7.541 (d, 1H, J = 9.6 Hz), 7.396 (m, 1H), 7.226 (ddd, 1H, J = 2.4 Hz, 2.4 Hz, 2.8 Hz), 6.055 (s, 1H), 3.860 (s, 3H), 3.769 (s, 2H), 3.710 (s, 3H), 3.695 (s, 4H), 2.588 (s, 4H), MS: 376 [M+1].
30. 36 using CCK-8 from Dojindo Laboratories. Percent inhibition of cytokine release compared to that of the control was calculated.
31. -4 M in absolute ethanol) solution. The contents of the reaction mixture were observed spectrophotometrically at 517 nm after 20 min. Gallic acid was used a reference drug (90.30%).
32. Bartolome B., Nunez V., Monagas M., and Gomes-Cardoves C. Eur. Food Res. Technol. 218 (2004) 173
33. Wright J.S. Chem. Ber. 39 (2003) 25
34. Nicolaides D., et al. Eur. J. Med. Chem. 33 (1998) 715
35. Hwang C., Catanaga M., Gale A., and Gatanaga T. J. Immunology 151 (1993) 5631
36. Dengler W.A., Shulte J., Berger D.P., Mertelsmann R., and Fiebig H.H. Anti-cancer Drugs 6 (1995) 522